We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

20 hedge funds and large institutions have $2.6M invested in vTv Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

0.06% less ownership

Funds ownership: 4.37% → 4.32% (-0.06%)

10% less capital invested

Capital invested by funds: $2.88M → $2.6M (-$276K)

13% less funds holding

Funds holding: 23 → 20 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
20
Holders Change
-3
Holders Change %
-13.04%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$48.4K
2
Northern Trust
Northern Trust
Illinois
+$7.82K
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.07K
4
BlackRock
BlackRock
New York
+$32

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$35K
2
VF
Virtu Financial
New York
-$27K
3
BCM
Bridgeway Capital Management
Texas
-$21.8K
4
Citadel Advisors
Citadel Advisors
Florida
-$19.6K
5
UBS Group
UBS Group
Switzerland
-$775

VTVT Hedge Fund Activity: Q2 2023 in Review

20 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q2 2023, worth a combined $2.6M — down 9.6% from $2.88M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of VTVT and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 4 added.

The largest buyer was Susquehanna International Group, adding an estimated $48.4K. The largest seller was Millennium Management, exiting entirely with an estimated $35K sold.

  • 20 institutional investors held vTv Therapeutics (VTVT) as of Q2 2023, down from 23 in Q1 2023.
  • Funds reported $2.6M of vTv Therapeutics stock for Q2 2023, down 9.6% quarter-over-quarter.
  • 2 funds opened new vTv Therapeutics positions in Q2 2023 and 5 closed out, a net change of -3 holders.
  • The largest vTv Therapeutics buyer in Q2 2023 was Susquehanna International Group, an estimated $48.4K added.
  • The largest vTv Therapeutics seller in Q2 2023 was Millennium Management, an estimated $35K sold.

Based on aggregated 13F filings for Q2 2023.